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Many  infections  worldwide  are  associated  with  bacterial  bioﬁlms.  The  effects  of  isolated  neolignans
(conocarpan  and  eupomathenoid-5)  and  the  dichloromethane  extract  of  Piper  regnellii  (Miq.)  C. DC.,
Piperaceae,  were  tested  against  isolates  of  methicillin-resistant  Staphylococcus  aureus  and  methicillin-
sensitive  S. aureus  bioﬁlms  and  S. aureus  planktonic  cells.  The  dichloromethane  extract  presented  better
results  than  isolated  neolignans  against  all of  the  bioﬁlms  tested,  with  a minimum  inhibitory  concen-
tration  <400  g/ml for preformed  bioﬁlms  and  minimal  bioﬁlm  inhibitory  concentration  of  15.6  g/mlioﬁlm
onocarpan
ichloromethane extract
upomathenoid-5
taphylococcus aureus
for  bioﬁlm  formation.  The  minimum  inhibitory  concentration  to  planktonic  cells was  <12.5  g/ml.  These
results  indicate  a good  effect  of  the  dichloromethane  extract  against  methicillin-resistant  S.  aureus  and
methicillin-sensitive  S. aureus  bioﬁlms  and  efﬁcient  prophylaxis.
© 2016  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Sociedade  Brasileira  de  Farmacognosia.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/ntroduction
Infections that are associated with antimicrobial resistance are
 primary challenge in public health, resulting in high rates of
orbidity and mortality, increased length of hospitalization, and
igher healthcare costs (Neidell et al., 2012). According to the
ational Institutes of Health (2002), approximately 80% of all infec-
ions worldwide are associated with bioﬁlms, especially those that
nvolve biomaterials.
Bioﬁlms are communities of microorganisms that are embed-
ed in an extracellular matrix that is composed of proteins, lipids,
olysaccharides, and nucleic acids. The members of a bioﬁlm are
rotected from environmental factors (e.g., ultraviolet light and
ehydration) and host immune cells (e.g., neutrophils and other
hagocytes) (Hall-Stoodley et al., 2004). Bioﬁlm-associated bacte-
ia are also much more resistant to antimicrobial agents (Stewart
nd Costerton, 2001).
Studies that investigate bioﬁlm physiology are important.
earching for new strategies to control this complex mode of bac-
erial life is extremely challenging (Trentin et al., 2013). Plants with
ntibacterial activity, such as the genus Piper, have shown promise.
∗ Corresponding author.
E-mail: bpdﬁlho@uem.br (B.P. Dias Filho).
http://dx.doi.org/10.1016/j.bjp.2016.08.008
102-695X/© 2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira
http://creativecommons.org/licenses/by-nc-nd/4.0/).4.0/).
Piper regnellii (Miq.) C. DC., popularly known in Brazil as “pari-
paroba,” is an herbaceous plant found to exist in tropical and
subtropical regions of the world (Cronquist, 1981). Leaves and roots
are used as crude extracts, infusions or platers to treat wounds,
reduction of swellings and skin irritations (Corrêa, 1984). Extracts
of the leaves of P. regnellii have shown good antibacterial activ-
ity against Staphylococcus aureus and Bacillus subtilis (Pessini et al.,
2003) and antifungal activity against the yeasts Candida albicans,
Candida krusei,  and Candida parapsilosis (Pessini et al., 2005). The
extract of the leaves and neolignan eupomatenoid-5 have also
shown activity against methicillin-resistant S. aureus (Marc¸ al et al.,
2010). Neolignans that are isolated from the leaves of P. regnellii also
have activity against the parasites Trypanosoma cruzi (Luize et al.,
2006) and Leishmania amazonensis (Vendrametto et al., 2010).
Because of the reported effect of P. regnellii against S. aureus,  the
aim of the present study was  to test a dichloromethane extract of P.
regnellii and isolated neolignans (conocarpan and eupomathenoid-
5) against methicillin-resistant S. aureus bioﬁlms and methicillin-
sensitive S. aureus bioﬁlms that were obtained from clinical
isolates.
Materials and methodsPlant material
Leaves from Piper regnellii (Miq.) C. DC., Piperaceae, were
collected in June 2012 in the Profa. Irenice Silva Medicinal Plant
 de Farmacognosia. This is an open access article under the CC BY-NC-ND license
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arden on the campus of the Universidade Estadual de Maringá
nd identiﬁed by Marilia Borgo of the Botany Department of the
niversidade Federal do Paraná. A voucher specimen (HUM 8392)
as deposited in the Herbarium of the Universidade Estadual de
aringá, Paraná, Brazil.
PLC analysis
The analyses were carried out using a Waters Binary HPLC
ump 1525, equipped with UV-VIS detector 2489, an autosampler
707 with a 20 l loop, and controlled by Breeze 2 Software. Chro-
atographic separations were carried out in a Phenomenex ODS
C18) Luna column, 5 m,  250 × 4.6 mm,  maintained at room tem-
erature, in an isocratic system, using acetonitrile–water acidiﬁed
ith 2% acetic acid (70:30, v/v) with a ﬂow rate of 1 ml/min. The
etection was carried out at 280 nm and the run time was 20 min.
onocarpan (1), eupomathenoid-6 (2) and eupomathenoid-5 (3)
ere quantiﬁed by external standardization, in method previously
alidated being linear, precise and accurate. Samples were diluted
n methanol, 1000 g/ml.
HO HO
2 R=H
3 R=OCH3
OO
R
1
solation of the constituents
Dried and powdered leaves of P. regnellii (300 g) were extracted
y maceration with ethanol:water (9:1) at room temperature in
 leaf:solvent ratio of 1:10 (w/v). The solvent was then removed
nder vacuum at 40 ◦C to give an aqueous extract and dark green
esidue that was washed with dichloromethane, yielding 24 g of
he dichloromethane extract (DE), and dried at room tempera-
ure, with yield of 8.2%. The DE (12 g) was subjected to vacuum
olumn chromatography with silica gel (230–400 mesh) and
luted with hexane (1000 ml), dichloromethane (1400 ml), ethyl
cetate (1000 ml), acetone (700 ml), and methanol (1000 ml). The
exane fraction resulted in the isolation of eupomathenoid-5 (3,
.05 g). The dichloromethane fraction (6 g) was  chromatographed
y column chromatography on silica gel 60 (230–400 mesh) with
exane:dichloromethane:ethyl acetate (12:7:1, v/v/v) to yield
onocarpan (1, 0.53 g) and eupomathenoid-6 (2), but in very small
uantity, 0.002 g. The column chromatography procedure was
onitored by thin layer chromatography (TLC) and used as the
obile phase, hexane:dichloromethane:ethyl acetate (12:7:1) and
anillin sulfuric 2%. Structures were identiﬁed by spectroscopy
UV, 1H NMR, 13C NMR, H–H COSY, gNOE, HETCOR, HMBC) and
omparisons with the literature (Achenbach et al., 1987; Chauret
t al., 1996; Snider et al., 1997).
acterial strains
The organisms used in this study were obtained of laboratory
ollection and were originated and identiﬁed in University Hospital
f Maringá. Ten clinical isolates of methicillin-resistant S. aureus
MRSA), strains 72, 73, 74, 76, 77, 78, 79, 81, 83 and 90 (with strains
2 and 73 obtained from blood and strains 74, 76, 77, 78, 79, 81,
3 and 90 obtained from secretion), and three clinical isolates of
nd methicillin-sensitive S. aureus (MSSA), strains 97, 170, and 212,
btained from urine (Marc¸ al et al., 2010). It was also used S. aureus
TCC 25923. Test strains were preserved in glycerol 10% at −80 ◦CFarmacognosia 27 (2017) 112–117 113
and were cultured on nutrient agar and incubated for 24 h at 37 ◦C
prior to determination of the minimum inhibitory concentration
(MIC).
Antibacterial susceptibility testing
The MIC  of conocarpan, eupomathenoid-5, and the DE  were
determined by a microdilution method in sterile ﬂat-bottom
microplates according to CLSI (2012) using Mueller-Hinton broth
(Merck S.A., São Paulo, Brazil). Inoculates were prepared in the same
medium at a density that was adjusted to a 0.5 McFarland turbidity
standard (108 colony-forming units [CFU]/ml) and diluted 1:10 for
the broth microdilution procedure. Conocarpan, eupomathenoid-
5 and DE were diluted and transferred into the ﬁrst well, and
serial dilutions 1:2 were performed so that concentrations in the
range of 100–1.56 g/ml were obtained. Vancomycin was used as
the reference antibacterial control in the range of 50–0.8 g/ml.
Positive control of strains (without presence of drugs) and nega-
tive control (with medium solely) was performed. Microtiter trays
were incubated at 37 ◦C, and the MICs were recorded after 24 h
of incubation. Three susceptibility endpoints were recorded for
each isolate. The MIC  was deﬁned as the lowest concentration
of the compounds at which the microorganism did not exhibit
visible growth. The minimum bactericidal concentration (MBC)
was performed in Mueller-Hinton agar, incubated at 37 ◦C during
24 h. MBC  was deﬁned as the lowest concentration that yielded
negative subcultures or only one colony. The in vitro results for
the drugs were classiﬁed as the following. MIC  <100 g/ml (good
antibacterial activity), MIC  = 100–500 g/ml (moderate antibacte-
rial activity), MIC  = 500–1000 g/ml (weak antibacterial activity),
and MIC  >1000 g/ml (no activity) (Pessini et al., 2003).
In vitro preformed bioﬁlm assay
Bioﬁlms of S. aureus ATCC 25923, 10 clinical isolates of MRSA,
and three clinical isolates of MSSA were formed on polystyrene
96-well microtiter plates. A 100 l suspension that contained
108 cells/ml in TSB medium with 1% glucose was seeded in wells
and incubated at 37 ◦C for 24 h. The well content was discharged,
and the wells were washed with phosphate-buffered saline (PBS).
Several dilutions of the DE, conocarpan, eupomathenoid-5, and
vancomycin (standard reference drug) (15.6–1000 g/ml) were
then added to each well. After incubation at 37 ◦C for 24 h, the
wells were rinsed with PBS. The MTT  reduction assay was per-
formed to evaluate the viability of the bioﬁlms. Three independent
assays were performed. The MTT  reduction assay was a slight mod-
iﬁcation of the method reported by Schillaci et al. (2008). The
MTT  solution (50 l; 2 mg/ml  in PBS) was added to each well, and
the plates were incubated at 37 ◦C for 2 h. After staining, the MTT
solution was  removed from each well, and 100 l of dimethylsulf-
oxide (DMSO) was added to dissolve the MTT  formazan product.
The DMSO (100 l) was  transferred to a new plate, and the opti-
cal density was  measured at 570 nm using a microplate reader.
Positive control of bioﬁlm formation (without treatment) and neg-
ative control (with medium solely) was performed. The results are
expressed as the MIC50, at which 50% of the sessile S. aureus cells
were inhibited compared with the control (without treatment) for
the MTT  assays.
Inhibiting bioﬁlm formation in vitro
This assay investigated the drugs ability to prevent bioﬁlm
formation. Brieﬂy, 100 l of drug (DE, conocarpan and
eupomathenoid-5) at different concentrations (15.6–1000 l/ml)
and standard drug, vancomycin in concentration 7.8–500 l/ml in
sterile TSB medium with 1% glucose was added to selected wells of
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 96-well microtiter plate, seeded with 100 l of a suspension that
ontained 108 cells/ml, and incubated for 24 h at 37 ◦C to allow
ioﬁlm formation. The contents of the wells were aspirated and
ashed three times in sterile PBS. The extent of bioﬁlm formation
as assessed by the MTT  reduction assay as described above. The
esults are expressed as the minimal bioﬁlm inhibitory concen-
ration (MBIC) compared with the control (without treatment) for
he MTT  assays.
canning electron microscopy
Scanning electron microscopy (SEM) was performed on glass
overslips by dispensing 400 l of the standardized cell suspen-
ions that contained 1.0 × 108 cells/ml of TSB supplemented with
% glucose into the wells of 24-well ﬂat-bottomed polystyrene
lates. To view preformed bioﬁlm, the plates were incubated at
7 ◦C for 24 h. After washing with PBS, conocarpan (110 g/ml)
nd the DE (370 g/ml) were added to preformed bioﬁlms, and the
lates were incubated for 24 h at 37 ◦C. To view bioﬁlm formation,
tandardized cell suspensions and drug (15.6 g/ml conocarpan,
1.5 g/ml eupomathenoid-5, 15.6 g/ml DE, and 7.8 g/ml van-
omycin) were added and incubated at 37 ◦C for 24 h. The coverslips
ere then washed twice with PBS and ﬁxed with 2.5% glutaralde-
yde overnight at 4 ◦C. The coverslips were then washed twice with
.1 M cacodylate buffer for 15 min  and dehydrated by replacing the
uffer with increasing concentrations of ethanol (30, 50, 70, 80,
0, 95, and 100%) for 10 min  each. After critical-point-drying and
oating with gold sputter, the samples were examined with a scan-
ing electron microscope, in Shimadzu SS-550 (Probe 4.0 and AccV
5.0 V).
esults and discussion
solation of the constituents
The extraction of P. regnellii (Miq.) C. DC. resulted in an 8.2%
ield of dichloromethane extract. From this extract, the use of
ilica gel chromatographic columns and a gradient system with
ncreasing degrees of polarity allowed the isolation of two major
ompounds that were present in the extract: conocarpan (1) and
upomathenoid-5 (3), and eupomathenoid-6 (2) in minor amount,
ot allowing use in biological assays. Conocarpan, with stereo-
hemistry (+)-conocarpan is the most abundant in nature, produced
aturally in plants of several families, and these molecules exhibit
 trans-dihydrobenzofuran heterocycle as a key structural element
Chen and Weisel, 2013). These substances were isolated and iden-
iﬁed by comparing spectroscopic data of 1H and 13C NMR  spectra
ith those previously published (Achenbach et al., 1987; Chauret
t al., 1996; Snider et al., 1997).
PLC analysis
Fig. 1 shows dichloromethane extract chromatogram. HPLC
nalysis allowed the neolignans quantiﬁcation. Dichloromethane
xtract DE was standardized in 135.32 g/ml of conocarpan
1), 91.90 g/ml of eupomathenoid-6 (2) and 106.98 g/ml of
upomthenoid-5 (3).
ntibacterial effect in planktonic cells
The MIC  results obtained in the study are shown in Table 1.
he dichloromethane extract had good activity against MRSA and
SSA, with MIC  <15 g/ml and MBC  <30 g/ml. These values
ere very similar to those reported by Marc¸ al et al. (2010). Cono-
arpan also had good activity against MRSA and MSSA (Table 1),Farmacognosia 27 (2017) 112–117
with a maximum MIC  = 50 g/ml and maximum MBC  = 100 g/ml.
Eupomathenoid-5 had a MIC  ≤6.25 g/ml and MBC  <25 g/ml.
The DE and isolated neolignans were tested against the standard
strain of S. aureus,  with a MIC  <15 g/ml and MBC  <30 g/ml
(Table 1). These values are similar to those reported in the literature
(Pessini et al., 2003; Felipe et al., 2008).
Antibacterial effect in preformed bioﬁlm
Resistance mechanisms of bioﬁlms are multifactorial and
depend on each organism. Although not fully understood, these
mechanisms can be attributed to such factors as a reduction of
the penetration of antibiotics through the bioﬁlm matrix, the
presence of slow-growing or non-growing cells in the bioﬁlm, a
heterogeneous bacterial population with the presence of pheno-
typic subpopulations with different levels of resistance, and the
persistent presence of cells (Mah  and O’Toole, 2001; Harrison et al.,
2005).
Table 1 shows good activity of the isolate neolignans against
planktonic cells, but the activity against the bioﬁlm was not the
same (Table 2). Euphomatenoid-5 showed no activity against S.
aureus ATCC 25923 bioﬁlm. However, conocarpan and the DE
had a satisfactory MIC50 against the bioﬁlm, 110 and 370 g/ml,
respectively (Table 2). These MTT  assay results demonstrate the
metabolic activity of the cells in the bioﬁlm, which was conﬁrmed
by SEM (Fig. 2).
The photomicrographs in Fig. 2A show the control bioﬁlm with
a large amount of adhered cells and an extracellular matrix. The
treated bioﬁlms (Fig. 2B and C) presented cellular lysis regions and
bioﬁlm detachment, suggesting the good action of conocarpan and
the DE against preformed bioﬁlms.
Although the concentration of conocarpan that was required
to combat the bioﬁlm was  less than the concentration of the DE,
the isolated substance showed no activity against clinical iso-
lates of MRSA and MSSA bioﬁlms (Table 2). The dichloromethane
extract was effective against all of the tested clinical isolates of
MRSA and MSSA bioﬁlms (MIC50 < 400 g/ml). In many parts of
the world, MRSA is responsible for a high rate of community-
and hospital-acquired S. aureus infections. The most important
classes of antibiotics that are used to prevent and treat S. aureus
infection are ineffective (Köck et al., 2010). In the present study,
dichloromethane extract of P. regnellii had better activity against S.
aureus bioﬁlms.
Antibacterial effect in inhibition bioﬁlm formation
An alternative to the control of bioﬁlm formation is to prevent
colonization. Thus, we  evaluated the ability of different concen-
trations of the DE, conocarpan, and eupomathenoid-5 to inhibit
the formation of bioﬁlms when added to the medium at the same
time as the cells. The results were compared with vancomycin. If an
agent is added at the beginning of the experiment, then the agent
might act before the bioﬁlm is formed and inhibit its development.
This could be of interest for combating recalcitrant infections (Khan
and Ahmad, 2012). Concentrations as low as 15.6 g/ml resulted in
a signiﬁcant reduction of the metabolic activity of adherent cells,
with >95% inhibition of MRSA and MSSA bioﬁlm formation com-
pared with untreated control cells (Table 3). The DE had results
that were very close to vancomycin for the inhibition of S. aureus
bioﬁlm formation.
These results were conﬁrmed by SEM. Fig. 3 shows the positive
control with a large number of cells that adhered to each other and
the presence an extracellular matrix (Fig. 3A). Photomicrographs
of cells that were treated with conocarpan (15.6 g/ml; Fig. 3B),
eupomathenoid-5 (31.2 g/ml; Fig. 3C), and the DE (15.6 g/ml;
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Fig. 1. Chromatographic proﬁle of dichloromethane extract of Piper regenelli at 1000 g/ml. (1) Conocarpan; (2) eupomatenoid-6; (3) eupomatenoid-5. Conditions: mobile
phase – acetonitrile:water with 2% acetic acid (70:30); ﬂow: 1 ml/min, detection at 280 nm.
Table 1
MIC  and MBC  of Piper regnellii dichloromethane extract, eupomathenoid-5, conocarpan and Vancomycin in S. aureus planktonic cells.
MIC (MBC) g/ml
Strains Dichloromethane extract Eupomathenoid-5 Conocarpan Vancomycin
72 12.5 (12.5) 6.25 (25) 50 (100) 1.56 (1.56)
73  12.5 (12.5) 6.25 (25) 50 (100) 1.56 (1.56)
74  6.25 (12.5) 6.25 (6.25) 25 (25) 1.56 (1.56)
76  6.25 (25) 6.25 (12.5) 25 (25) 1.56 (1.56)
77  12.5 (25) 6.25 (12.5) 25 (25) 1.56 (1.56)
78  6.25 (12.5) 3.13 (6.25) 12.5 (100) 1.56 (1.56)
79  12.5 (25) 3.13 (6.25) 25 (25) 1.56 (1.56)
81  12.5 (25) 3.13 (6.25) 25 (50) 1.56 (1.56)
83  6.25 (12.5) 3.13 (6.25) 25 (100) 1.56 (1.56)
90  6.25 (25) 3.13 (6.25) 25 (100) 1.56 (1.56)
97  12.5 (25) 6.25 (6.25) 12.5 (12.5) 1.56 (1.56)
170  12.5 (25) 6.25 (12.5) 12.5 (12.5) 1.56 (1.56)
212  12.5 (25) 6.25 (12.5) 12.5 (25) 1.56 (1.56)
ATCC  25923 6.25 (12.5) 6.25 (12.5) 12.5 (25) 1.56 (1.56)
The MIC  results were considered good antibacterial activity (MIC < 100 g/ml).
Table 2
MIC50 of Piper regnellii dichloromethane extract, eupomathenoid-5, conocarpan and vancomycin to S. aureus preformed bioﬁlms.
MIC50 (g/ml)
Strains Dichloromethane extract Eupomathenoid-5 Conocarpan Vancomycin
72 300 – >1000 –
73  170 – – –
74  50 – – –
76  360 – – –
77  390 – >1000 –
78  180 – >1000 –
79  190 – >1000 –
81  210 – >1000 –
83  230 – >1000 –
90  130 – >1000 –
97  260 – >1000 –
170  260 – >1000 –
212  370 – >1000 –
ATCC  25923 370 – 110 –
MIC50, minimal inhibitory concentration at which 50% of the sessile S. aureus cells were inhibited.
Fig. 2. Scanning electron micrographs of randomly chosen areas of S. aureus ATCC 25923 bioﬁlm at 24 h. (A) Positive control. (B) Bioﬁlm treated with 370 g/ml of
dichloromethane extract. (C) Bioﬁlm treated with 110 g/ml of conocarpan. 7000 magniﬁcation.
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Table  3
Minimal bioﬁlm inhibitory concentration (MBIC) values for the Piper regnellii dichloromethane extract, eupomathenoid-5, conocarpan and vancomycin to S. aureus bioﬁlms
formation.
MBIC (g/ml)
Strains Dichloromethane extract Eupomathenoid-5 Conocarpan Vancomycin
72 15.6 15.6 15.6 7.8
73  15.6 15.6 15.6 7.8
74  15.6 31.2 15.6 7.8
76  15.6 31.2 15.6 7.8
77  15.6 250 125 7.8
78  15.6 15.6 15.6 7.8
79  15.6 15.6 15.6 15.6
81  15.6 15.6 15.6 7.8
83  31.2 31.2 31.2 62.5
90  15.6 15.6 15.6 7.8
97  15.6 15.6 15.6 7.8
170  15.6 15.6 15.6 7.8
212  15.6 15.6 15.6 7.8
ATCC  25923 15.6 31.2 15.6 7.8
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aig. 3. Scanning electron micrographs of randomly chosen areas of S. aureus AT
15.6  g/ml). (C) Bioﬁlm treated with eupomathenoid-5 (31.25 g/ml). (D) Bioﬁlm
7.8  g/ml). 3000 magniﬁcation. This study was  performed according to the interna
ig. 3D) showed isolated and fewer cells compared with van-
omycin (Fig. 3E).
Bioﬁlm-related infections are an important cause of healthcare-
ssociated infections (Darouiche, 2004). Bioﬁlm-embedded bacte-
ia are challenging to treat because they display tolerance to
ntibiotics and the host’s immune system (John et al., 2011; Leite
t al., 2011). Traditional antibiotics that were developed to kill
lanktonic bacteria often have limited effects on sessile bacteria
hat are encased within a bioﬁlm. Additionally, the development
f antimicrobial resistance is common in sessile bacteria. Thus,
here is an urgent need to develop non-antimicrobial treatment
trategies to prevent or treat bioﬁlm-associated infections (Kuehn,
011).
onclusionGood results were achieved with the dichloromethane extract
f P. regnellii (Miq.) C. DC. and isolated neolignans conocarpan
nd eupomathenoid-5 against planktonic cells of S. aureus MRSA
nd MSSA, similar to the standard drug vancomycin. Similar good923 bioﬁlm formation. (A) Positive control. (B) Bioﬁlm treated with conocarpan
d with dichloromethane extract (15.6 g/ml), D Bioﬁlm treated with vancomycin
, national and institutional rules considering clinical studies and biodiversity rights.
effects were found against bioﬁlm formation. The dichloromethane
extract and isolated neolignans also showed activity that was close
to vancomycin and appeared to be effective as a prophylactic
alternative. The DE was also effective against S. aureus MRSA and
MSSA preformed bioﬁlms. These results support the application of
this extract of P. regnellii as an alternative agent against bioﬁlm-
associated bacterial infections.
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